Population pharmacokinetic and pharmacodynamic analysis of tremelimumab in patients with metastatic melanoma

Journal of Clinical Pharmacology

Volumn 54, Issue 10, 2014, Pages 1108-1116

  Wang, Erjian ^a   Kang, Dongwoo ^a   Bae, Kyun Seop ^b   Marshall, Margaret A ^a   Pavlov, Dmitri ^c   Parivar, Kourosh ^a  

^a PFIZER INC   (United States)

^b University of Ulsan   (South Korea)

^c Pfizer Ltd   (United States)

Author keywords

drug clearance; malignancy; melanoma; overall survival; population pharmacokinetic; tremelimumab

Indexed keywords

ALANINE AMINOTRANSFERASE; BILIRUBIN; C REACTIVE PROTEIN; IMMUNOGLOBULIN; LACTATE DEHYDROGENASE; TICILIMUMAB;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BILIRUBIN BLOOD LEVEL; BODY WEIGHT; CANCER PATIENT; CANCER STAGING; CONTROLLED STUDY; CREATININE CLEARANCE; DRUG CLEARANCE; DRUG EFFICACY; ELECTROCORTICOGRAPHY; FEMALE; HUMAN; LACTATE DEHYDROGENASE BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; METASTATIC MELANOMA; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; TREATMENT DURATION; VOLUME OF DISTRIBUTION;

EID: 85027916593     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1002/jcph.309     Document Type: Article

References (24)

1. Camacho LH,. Novel therapies targeting the immune system: CTLA4 blockade with tremelimumab (CP-675,206), a fully human monoclonal antibody. Expert Opin Investig Drugs. 2008; 17: 371-385.
2. Ribas A, Hanson DC, Noe DA, et al. Tremelimumab (CP-675,206), a cytotoxic T lymphocyte associated antigen 4 blocking monoclonal antibody in clinical development for patients with cancer. Oncologist. 2007; 12: 873-883.
3. Leach DR, Krummel MF, Allison JP,. Enhancement of antitumor immunity by CTLA-4 blockade. Science. 1996; 271: 1734-1736.
4. Camacho LH, Antonia S, Sosman J, et al. Phase I/II trial of tremelimumab in patients with metastatic melanoma. J Clin Oncol. 2009; 27: 1075-1081.
5. Ribas A, Camacho LH, Lopez-Berestein G, et al. Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206. J Clin Oncol. 2005; 23: 8968-8977.
6. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010; 363: 711-723.
7. Robert C, Thomas L, Bondarenko I, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med. 2011; 364: 2517-2526.
8. Wolchok JD, Kluger H, Callahan MK, et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med. 2013; 369: 122-133.
9. Ribas A, Kefford R, Marshall MA, et al. Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma. J Clin Oncol. 2013; 31 (5): 616-622.
10. Kang D, Wang E, Wang D, et al. Population pharmacokinetics (PK) of tremelimumab in patients (pts) with melanoma [abstract]. J Clin Oncol. 2009; 27 (Suppl): Abstract no. 3048.
11. Lu J, Gaudreault J, Novotny W, et al. A population pharmacokinetic model for bevacizumab [abstract]. Clin Pharmacol Ther. 2004; 75: P91.
12. Keizer RJ, Huitema AD, Schellens JH, et al. Clinical pharmacokinetics of therapeutic monoclonal antibodies. Clin Pharmacokinet. 2010; 49 (8): 493-507.
13. Gibiansky L, Sutjandra L, Doshi S, et al. Population pharmacokinetic analysis of denosumab in patients with bone metastases from solid tumours. Clin Pharmacokinet. 2012; 51: 247-260.
14. Bruno R, Washington CB, Lu JF, et al. Population pharmacokinetics of trastuzumab in patients with HER2+ metastatic breast cancer. Cancer Chemother Pharmacol. 2005; 56: 361-399.
15. Dowell JA, Korth-Bradley J, Liu H, et al. Pharmacokinetics of gemtuzumab ozogamicin, an antibody targeted chemotherapy agent for the treatment of patients with acute myeloid leukemia in first relapse. J Clin Pharmacol. 2001; 41: 1206-1211.
16. Berinstein NL, Grillo-Lopez AJ, White CA, et al. Association of serum rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of reccurent low-grade or follicular non-Hodgkin's lymphoma. Ann Oncol. 1998; 9: 995-1001.
17. Davies TA, White CA, Grillo-Lopez AJ, et al. Single-agent monoclonal antibody efficacy in bulky non-Hodgkin's lymphoma: results of a phase II trial of rituximab. J Clin Oncol. 1999; 17: 1851-1857.
18. Harris KA, Washington CB, Lieberman G, et al. A population pharmacokinetic model for trastuzumab (Herceptin) and implications for clinical dosing [abstract]. Proc Am Soc Clin Oncol. 2002; 21: 123a.
19. Palmer SR, Erickson LA, Ichetovkin I, et al. Circulating serologic and molecular biomarkers in malignant melanoma. Mayo Clin Proc. 2011; 86 (10): 981-990.
20. Heikkilä K, Ebrahim S, Rumley A, et al. Associations of circulating C-reactive protein and interleukin-6 with survival in women with and without cancer: findings from the British Women's Heart and Health Study. Cancer Epidemiol Biomarkers Prev. 2007; 16 (6): 1155-1159.
21. Genentech, Inc. Bevacizumab. Drugs Fut. 2002; 27 (7): 625-632.
22. Fasanmade AA, Adedokun OJ, Ford J, et al. Population pharmacokinetic analysis of infliximab in patients with ulcerative colitis. Eur J Pharmacol. 2009; 65: 1211-1228.
23. Wolbink GJ, Voskuyl AE, Lems WF, et al. Relationship between serum trough infliximab levels, pretreatment C reactive protein levels, and clinical response to infliximab treatment in patients with rheumatoid arthritis. Ann Rheum Dis. 2005; 64: 704-707.
24. Azzopardi N, Lecomte T, Ternant D, et al. Cetuximab pharmacokinetics influences progression-free survival of metastatic colorectal cancer patients. Clin Cancer Res. 2011; 17: 6329-6337.